Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 22.43 USD -12.76% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Viridian Therapeutics Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Viridian Therapeutics Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Viridian Therapeutics Inc
NASDAQ:VRDN
Cash & Cash Equivalents
$107.7m
CAGR 3-Years
57%
CAGR 5-Years
35%
CAGR 10-Years
30%
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%

See Also

What is Viridian Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
107.7m USD

Based on the financial report for Jun 30, 2024, Viridian Therapeutics Inc's Cash & Cash Equivalents amounts to 107.7m USD.

What is Viridian Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
30%

Over the last year, the Cash & Cash Equivalents growth was 24%. The average annual Cash & Cash Equivalents growth rates for Viridian Therapeutics Inc have been 57% over the past three years , 35% over the past five years , and 30% over the past ten years .

Back to Top